Nasdaq:CRMD
CorMedix Inc.
CorMedix (CRMD) develops proprietary medical devices for wound care and surgical markets with a recent revenue jump to $43.5M and substantial cash reserves.
Key Metrics
Investment Thesis
Bull Case
Investors may buy CorMedix based on the dramatic revenue expansion from $0.1M to $43.5M, suggesting successful product commercialization and market penetration. The company retains a healthy liquidity buffer of $40.8M against total liabilities of $34.2M, providing runway to weather losses while scaling operations. Proprietary medical device platforms in the growing wound care sector offer potential for high-margin growth once sales volumes stabilize.
Bear Case
The stock is risky given three consecutive years of negative net income, with the deficit widening before narrowing slightly in 2024. Operating cash flow remains deeply negative at -$50.6M, indicating that current revenue levels are insufficient to cover operational costs without external capital. The massive retained earnings deficit of $339.6M signals long-term solvency concerns if the company cannot achieve breakeven soon.
About CorMedix Inc.
CorMedix Inc. (CRMD) is a medical device company focused on developing innovative solutions for wound care and surgical applications, primarily serving hospitals and healthcare facilities in North America. The company's revenue of $43.5M in 2024 reflects growth from negligible levels in prior years, driven by the commercialization of its proprietary product portfolio. Despite reporting a net loss of $17.9M for the year, the firm maintains a strong cash position of $40.8M to fund ongoing research and development.
Analysis
Management Discussion
Management has successfully transitioned the company from a near-zero revenue state in 2022 to generating $43.5M in revenue by 2024, marking a pivotal growth phase. However, profitability remains elusive with an operating profit of -$22.4M, largely driven by high general and administrative costs totaling $30.0M. The cash flow from operations turned negative at -$50.6M, necessitating continued equity financing to sustain burn rates despite maintaining over $40M in cash equivalents.
Industry Overview
The medical device industry is characterized by high R&D requirements and regulatory hurdles, yet offers substantial growth potential in specialized areas like chronic wound care. Competitors range from large multinational corporations to smaller biotech firms, creating a fragmented landscape where innovation can drive market share. Companies in this sector often face margin pressure initially due to sales force development and marketing costs before achieving profitability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $65.4K | $0 | $43.5M |
| Cost of Revenue | $3.7K | $0 | $3.2M |
| Gross Profit | $61.7K | $0 | $40.3M |
| Operating Expenses | $30.7M | $49.0M | $62.6M |
| Operating Income | $-30.6M | $-49.0M | $-22.4M |
| R&D | $10.7M | $13.2M | $3.9M |
| G&A | $20.0M | $35.8M | $30.0M |
| Marketing | — | — | $28.7M |
| Stock-Based Comp | $4.1M | $5.5M | $6.1M |
| Depreciation | $84.6K | $70.8K | $153.9K |
| Amortization | — | — | $155.8K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $336.6K | $3.0M | $3.0M |
| Interest Expense | $26.5K | $34.3K | — |
| Interest Income | $326.0K | $2.7M | $2.6M |
| Pre-Tax Income | $-30.3M | $-45.9M | $-19.3M |
| Income Tax | $-585.6K | $393.2K | $-1.4M |
| Continuing Ops | $-29.7M | $-46.3M | $-17.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-29.7M | $-46.3M | $-17.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-29.7M | $-46.3M | $-17.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $59.6M | $79.5M | $114.6M |
| Cash & Equivalents | $43.1M | $43.6M | $40.7M |
| Marketable Securities | $15.6M | $32.4M | $11.0M |
| Accounts Receivable | — | — | $51.7M |
| Inventory | — | $2.1M | $7.6M |
| Prepaid Expenses | $623.7K | $882.2K | $3.5M |
| Other Current Assets | $135.1K | $431.0K | $152.8K |
| Long-Term Assets | $2.5M | $2.6M | $4.3M |
| PP&E (Net) | $1.6M | $1.9M | $1.8M |
| Intangibles | — | — | $1.8M |
| Operating Leases | $775.1K | $640.3K | $492.7K |
| Other LT Assets | $102.3K | $103.1K | $105.4K |
| Total Assets | $62.0M | $82.1M | $118.8M |
| Current Liabilities | $6.3M | $11.4M | $33.8M |
| Accounts Payable | $2.2M | $4.3M | $1.7M |
| Current Leases | $134.8K | $150.6K | $167.9K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $667.6K | $517.0K | $349.1K |
| LT Operating Leases | $667.6K | $517.0K | $349.1K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $7.0M | $11.9M | $34.2M |
| Shareholders' Equity | $55.1M | $70.1M | $84.7M |
| Paid-In Capital | $330.3M | $391.7M | $424.1M |
| Retained Earnings | $-275.4M | $-321.7M | $-339.6M |
| AOCI | $82.7K | $94.1K | $90.6K |
| Total L&E | $62.0M | $82.1M | $118.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-29.7M | $-46.3M | $-17.9M |
| Non-Cash Adjustments | $5.7M | $284.7K | $-112.6M |
| Working Capital Changes | $-360.3K | $7.6M | $80.0M |
| Cash from Operations | $-24.4M | $-38.4M | $-50.6M |
| Capital Expenditures | $219.4K | $327.3K | $115.7K |
| Cash from Investing | $-3.7M | $-17.1M | $21.2M |
| Cash from Financing | $17.9M | $55.9M | $26.3M |
| FX Effect | $-8.7K | $2.8K | $-1.7K |
| Net Change in Cash | $-10.2M | $448.4K | $-3.1M |
| Beginning Cash | $53.6M | $43.4M | $43.8M |
| Ending Cash | $43.4M | $43.8M | $40.8M |
Frequently Asked Questions
How does CorMedix Inc. make money?
The company operates primarily through its core medical device segment, generating revenue from the sale of advanced wound management products and surgical instruments. Additional revenue streams likely include licensing agreements or partnerships related to intellectual property development, though specific segment breakdowns are not detailed in the provided financials. The business model relies heavily on high-margin product sales supported by significant marketing investments of $28.7M.
What are the main risks for CRMD?
The company faces significant financial risk due to a substantial retained earnings deficit of $339.6M and recurring net losses over the last three years. Heavy reliance on share issuances ($18.9M in 2024) to finance operations dilutes existing shareholders and indicates an inability to generate positive operating cash flow. The aggressive marketing spend of $28.7M against only $43.5M in total revenue creates high vulnerability if product uptake slows or if competitors undercut pricing.
What is CRMD's competitive advantage?
CorMedix possesses proprietary technology and patents that differentiate its wound care solutions from generic competitors in a specialized market. The company has established strategic relationships with major healthcare institutions, ensuring initial distribution channels for its new product launches. Its lean operational structure, evidenced by low accounts payable ($1.7M) relative to receivables, suggests efficient working capital management within the niche medical device space.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.